Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills
In This Article:
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.
Terms and Privacy Policy